公开(公告)号：US20070213373A1

公开(公告)日：2007-09-13

申请号：US11799605

申请日：2007-05-02

申请人： Richard Cournoyer ,  David Loughhead ,  Counde O'Yang

发明人： Richard Cournoyer ,  David Loughhead ,  Counde O'Yang

IPC分类号： A61K31/416 ,  A61K31/4439

CPC分类号： C07D209/44 ,  C07D231/56 ,  C07D401/04

摘要： This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein R3 is optionally substituted aryl or heteroaryl, R1 and R2 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents.

摘要翻译： 本发明涉及通常为CRF-1受体拮抗剂并由式I或式II表示的化合物：其中R 3是任选取代的芳基或杂芳基，R 1， 和R 2如本说明书中所定义; 或各异构体，异构体的外消旋或非外消旋混合物或其药学上可接受的盐。 本发明还涉及制备这些化合物的方法，含有这些化合物的药物组合物及其用作治疗剂的方法。

公开(公告)号：US20050038052A1

公开(公告)日：2005-02-17

申请号：US10916582

申请日：2004-08-11

申请人： Robin Clark ,  Richard Cournoyer ,  Counde O'Yang

发明人： Robin Clark ,  Richard Cournoyer ,  Counde O'Yang

IPC分类号： A61P25/24 ,  C07D239/94 ,  A61K31/517 ,  C07D43/02

CPC分类号： C07D239/94

摘要： Compounds of the formula (I): and pharmaceutically acceptable salts or prodrugs thereof, wherein m, R1, R2, R3, R4, R5 and R6 are as defined herein. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula (I).

摘要翻译： 式（I）化合物及其药学上可接受的盐或前药，其中m，R 1，R 2，R 3，R 4，R 5和R 6为 本文定义。 本发明还提供了制备方法，组合物和使用式（I）化合物的方法。

公开(公告)号：US4894162A

公开(公告)日：1990-01-16

申请号：US187035

申请日：1988-04-27

申请人： Richard Cournoyer ,  Thomas Jakopp ,  G. E. Friberg

发明人： Richard Cournoyer ,  Thomas Jakopp ,  G. E. Friberg

IPC分类号： B01D53/84 ,  C02F1/66 ,  C02F3/02 ,  C02F3/12 ,  C02F3/20 ,  C02F3/34

CPC分类号： C02F3/1215 ,  B01D53/84 ,  C02F1/66 ,  C02F3/025 ,  C02F3/1221 ,  C02F3/1226 ,  C02F3/205 ,  C02F3/34 ,  Y02W10/15 ,  Y10S210/916

摘要： A method and apparatus for purifying industrial waste fluids by an aerobic biological treatment is provided herein, which is capable of concurrently purifying waste gases emanating from such waste liquids. The improvement relates to the elimination or reduction of odors and volatile organic substances by enclosing all tanks and basins from the influent of the waste water treatment plant up to the aeration treatment zone for the liquid waste water and venting these gases to an aerobic digester and/or an aeration basin to biologically decompose or degrade the VOS in the waste gas by action of the microorganisms in the aeration basin or aerobic digester.

公开(公告)号：US20060035870A1

公开(公告)日：2006-02-16

申请号：US11240547

申请日：2005-09-30

申请人： Richard Cournoyer ,  Paul Keitz ,  Lee Lowrie ,  Alexander Muehldorf ,  Counde O'Yang ,  Dennis Yasuda

发明人： Richard Cournoyer ,  Paul Keitz ,  Lee Lowrie ,  Alexander Muehldorf ,  Counde O'Yang ,  Dennis Yasuda

IPC分类号： A61K31/60 ,  C07D215/14 ,  C07D263/60

CPC分类号： C07D263/56 ,  C07C271/22 ,  C07C311/08 ,  C07C311/21 ,  C07D209/08 ,  C07D215/14 ,  C07D235/18 ,  C07D307/12 ,  C07D307/80 ,  C07D405/14 ,  C07D409/04

摘要： This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: wherein: R1, R2, and R3 are each independently in each occurrence aryl or heteroaryl; R4is —COOH or tetrazolyl; A, B, m, n, and r are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and processes for their preparation.

摘要翻译： 本发明涉及通常为IP受体拮抗剂并由式I表示的化合物：其中：R 1，R 2和R 3， 各自独立地为芳基或杂芳基; R 4是-COOH或四唑基; A，B，m，n和r如说明书中所定义; 或各异构体，异构体的外消旋或非外消旋混合物，或其药学上可接受的盐或溶剂合物。 本发明还涉及含有这些化合物的药物组合物，其用作治疗剂的方法及其制备方法。

公开(公告)号：US20050124607A1

公开(公告)日：2005-06-09

申请号：US10884595

申请日：2004-07-02

申请人： Elbert Chin ,  Richard Cournoyer ,  Paul Keitz ,  Eun Lee ,  Francisco Lopez-Tapia ,  Chris Melville ,  Fernando Padilla ,  Klaus Weinhardt

发明人： Elbert Chin ,  Richard Cournoyer ,  Paul Keitz ,  Eun Lee ,  Francisco Lopez-Tapia ,  Chris Melville ,  Fernando Padilla ,  Klaus Weinhardt

IPC分类号： A61K31/517 ,  A61K31/549 ,  A61P13/00 ,  C07D239/95 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/02 ,  C07D451/02 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D491/10 ,  C07D498/10 ,  C07D43/02

CPC分类号： C07D401/04 ,  C07D239/95 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D451/02 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D491/10

摘要： Compounds which are alpha-1A/B adrenoceptor antagonists and which are represented by Formula I: wherein Q is a monocyclic or bicyclic optionally-substituted heterocyclic ring as defined herein; Z is —C(═O)— or —S(═O)2—; R and R′ are lower alkyl; R5 is halogen, cyano, hydroxy, —R6, or —OR6; and R6 is alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclo, or substituted heterocyclo; and pharmaceutically-acceptable salts, hydrates, prodrugs, and isomers thereof.

摘要翻译： 作为α-1A / B肾上腺素受体拮抗剂并由式I表示的化合物：其中Q是如本文所定义的单环或双环任选取代的杂环; Z是-C（-O） - 或-S（-O）2 - 。 R和R'是低级烷基; R 5是卤素，氰基，羟基，-R 6或-OR 6; R 6是烷基，取代的烷基，芳基，取代的芳基，杂芳基，取代的杂芳基，环烷基，取代的环烷基，杂环或取代的杂环; 及其药学上可接受的盐，水合物，前体药物和异构体。

公开(公告)号：US5106496A

公开(公告)日：1992-04-21

申请号：US725382

申请日：1991-06-27

申请人： Richard Cournoyer ,  Thomas Jakopp ,  G. Eric Friberg

发明人： Richard Cournoyer ,  Thomas Jakopp ,  G. Eric Friberg

IPC分类号： B01D53/84 ,  C02F1/66 ,  C02F3/02 ,  C02F3/12 ,  C02F3/20 ,  C02F3/34

CPC分类号： C02F3/1215 ,  B01D53/84 ,  C02F1/66 ,  C02F3/025 ,  C02F3/1221 ,  C02F3/1226 ,  C02F3/205 ,  C02F3/34 ,  Y02W10/15

摘要： A method and apparatus for purifying industrial waste fluids by an aerobic biological treatment is provided herein, which is capable of concurrently purifying waste gases emanating from such waste liquids. The improvement relates to the elimination or reduction of odors and volatile organic substances by enclosing all tanks and basins from the influent of the waste water treatment plant up to the aeration treatment zone for the liquid waste water and venting these gases to an aerobic digester and/or an aeration basin to biologically decompose or degrade the VOS in the waste gas by action of the microorganisms in the aeration basin or aerobic digester.

摘要翻译： 本文提供了一种通过需氧生物处理净化工业废液的方法和装置，其能够同时净化从这种废液发出的废气。 该改进涉及消除或减少气味和挥发性有机物质，包括从废水处理厂的流入物到液体废水的曝气处理区的所有罐和盆，将这些气体排放到需氧消化器和/ 或曝气池，以通过曝气池或有氧消化器中微生物的作用来生物分解或降解废气中的VOS。